AIOS GLP-1 wrapper strategy

This is a bet that obesity care is large enough to be its own telehealth category leader, not just an add on product. AIOS is using one recurring drug workflow across three fronts, Fella for US men, Delilah for US women, and Bolt in the UK, then centralizing the expensive work underneath, intake, prescriber review, titration, side effect follow up, cold chain fulfillment, and refills.

• Ro and Hims first built big brands on simpler, high margin generics like ED and hair loss, then added GLP-1s later. AIOS started from GLP-1s and stayed there, which works because these patients need ongoing dose changes and monthly shipments, creating a much deeper repeat care loop than a one time prescription.
  1 sacra 2 sacra
• The operating system matters more than the molecule brand. Ro turned GLP-1 care into a managed subscription with labs, clinician messaging, and pharmacy routing. AIOS is applying the same logic, but instead of cross selling many conditions, it is segmenting the same obesity workflow by audience and geography.
  1 sacra 2 sacra 3 sacra
• The tradeoff is margin versus speed. Bolt became the cheapest regulated branded GLP-1 source in the UK by selling at cost, which helped AIOS scale to about 150,000 patients and $420M annualized revenue by June 2026, but with roughly pharmacy like 20% gross margins versus the 65% to 80% fulfillment margins Ro and Hims have historically earned.
  1 sacra 4 sacra 5 sacra

The next phase is turning this single molecule play into a Europe wide pharmacy network, then eventually into a manufacturer once semaglutide patents roll off in the early 2030s. If that happens, AIOS moves from being a high volume wrapper around pharma supply to owning both the patient relationship and much more of the drug economics.